Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New bacteraemia standards in Ireland:

This article was originally published in Clinica

Executive Summary

Ireland is to set "explicit targets" for the control of bloodstream infections associated with medical technology use. A package of measures aimed at tightening the control of healthcare-associated infections (HAIs) over the next five years will include standards on surgical site and central venous line-associated infections, as well as an enhanced bacteraemia surveillance regime. The Health Service Executive aims to cut HAIs generally by 20% and methicillin-resistant Staphylococcus aureus (MRSA) specifically by 30%. Citing independent data collected during February-May 2006, it said that at 4.9% overall prevalence, Ireland still compares favourably with other countries: from Australia at 6%, to Denmark and Spain at 8%; France and the US are given a prevalence range of between 5-6% and 10%. Norway, the Netherlands and the UK reportedly stood at around 7%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel